Elan Corp. Plc

Nodenza Venture Partners launched Focus on international early-stage and pre-commercial biotech & medtech opportunities New York, October 16, 2024 – Nodenza Venture Partners (“Nodenza”) has been launched to provide financial and operational support to early-stage and pre-commercial biotech and medtech companies and products. Established by a team of experienced life sciences entrepreneurs, founders and leaders, Nodenza already has a pipeline of unique high value opportunities. Ross Morton, Managing Partner of Nodenza Venture Partners, said: “Nodenza is focused on identifying, investing in and supporting disruptive technologies and therapies with the potential to deliver exceptional benefits to patients which Nodenza believes to be the most successful driver of long-term capital returns. Our expert team has a strong track record of delivering success in the life sciences industry.” Nodenza’s bi-modal investment strategy combines early-stage opportunities – advancing new treatment modalities through active IND to phase 2 - with pre-commercial targets supporting their transition from scientific to commercial companies delivering strong upside potential. The approach leverages Nodenza’s expertise in the creation and growth of new companies, as well as late-stage product development and launch. “Our leadership team blends strong drug development and process skills to ensure we invest in the best opportunities, with hands-on mentorship and guidance to support the optimal growth of portfolio companies. We are targeting three to four investments in the first year of operation and look forward to working alongside other venture partners to maximize our impact and build a portfolio of innovative and well-resourced companies,” Morton said. The Nodenza team includes: Ross Morton, Managing Director, former COO of Akaza Bioscience and head of strategy and operations at Izana Bioscience, sold to Roivant in 2020.Dr Tim Corn, Partner, a specialist in clinical & regulatory affairs with extensive experience as Chief Medical Officer involved in more than 20 FDA & EMA approvals; formerly at GSK, Elan & the UK Medicines and Healthcare Products Regulatory Agency (MHRA).Bryan Morton, Chairman and Partner, formerly EUSA Pharma CEO & Chairman, Private Equity Operating Partner and with extensive commercialization experience; previously at Merck & BMS.Dr Dev Kumar, Partner, former GC of EUSA Pharma with expertise in IP and market access; Dr Kumar has worked at Biogen, UCB and BI and qualified as a medical doctor & lawyer.Dr Gary Whale, Partner, the CTO of Zura Bio with expertise in CMC and product launch; formerly at EUSA Pharma, VHsquared and P&G. Nodenza is in the process of establishing an Advisory Board. Contacts: Nodenza Venture Partners Ross Morton, Managing Partnerinfo@nodenza.com Mo Advisory PRmo@mopradvisory.comMo Noonan / Jonathan Birt Notes to Editors About Nodenza Venture PartnersNodenza Venture Partners provides investment and operational support to early-stage and pre-commercial biotech and medtech companies and products designed to bring exceptional patient benefit. Our bi-modal investment strategy combines early-stage opportunities – advancing new treatment modalities through active IND to phase 2 - with pre-commercial targets supporting their transition from scientific to commercial companies delivering strong upside potential. Established by a team of experienced life sciences entrepreneurs, founders and leaders, our approach leverages Nodenza’s extensive expertise in the creation and growth of new companies, as well as late-stage product development and launch. For more information visit us at https://www.nodenza.com Attachment Nodenza Launch Final

BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry. “It is a privilege to welcome Erik to the Inozyme Board of Directors at this exciting juncture for Inozyme as we continue to lay the groundwork for our transition into a commercial-stage company,” said Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma. “Erik’s track record of spearheading successful launches for rare disease therapies, combined with his deep commercial insights, will be invaluable as we advance INZ-701 through late-stage development and prepare to bring this important program to patients.” Mr. Harris added: “INZ-701 holds significant promise as an important new therapy for a broad range of serious rare diseases affecting bone health and blood vessel function. I look forward to collaborating with Inozyme’s talented team as they work toward unlocking the full potential of this innovative therapy for patients who urgently need it.” Prior to his appointment as Chief Commercial Officer, Mr. Harris served as the Senior Vice President and Head of North American Commercial Operations at Ultragenyx. Before joining Ultragenyx, he spent six years at Crescendo Bioscience, most recently as Vice President of Commercial. Earlier in his career, Mr. Harris served as Vice President of Marketing at Intermune, Inc., and held positions in the commercial organizations at Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol-Myers Squibb Company. He currently serves on the Board of Directors at Denali Therapeutics. At the start of his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy. Mr. Harris received his M.B.A. from the Wharton School of Business, and a B.S. from the United States Naval Academy. About Inozyme Pharma Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL). Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook. Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, timing, and design of our planned clinical trials, availability of data from clinical trials, the potential benefits of INZ-701, our regulatory strategy, including our planned pathway to approval for the ABCC6 Deficiency program, and the period over which we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our cash flow requirements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to conduct its ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis; enroll patients in ongoing and planned trials; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; comply with covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. Contacts Investors:Inozyme PharmaStefan Riley, Senior Director of IR and Corporate Communications(857) 330-8871stefan.riley@inozyme.com Media:Biongage CommunicationsTodd Cooper(617) 840-1637Todd@biongage.com

Jack O’Meara announced on LinkedIn Monday that he is stepping down from the CEO post at Ochre Bio, the liver disease startup he co-founded. In an interview with Endpoints News , he teased plans for a neurodegenerative disease startup, though he said work is still in its early phases. Ochre Bio has inked partnerships with both GSK and Boehringer Ingelheim in the past year. “It’s a big job. It takes its toll. And I felt after the two deals, we put the company in a really strong position for its next phase,” O’Meara said about his decision to leave Ochre now. “My skill set lends itself quite well to building early-stage companies and getting platforms off the ground,” he added. Eliot Forster will become executive chairman of Ochre Bio, steering the company as it finds a new CEO “in due course.” O’Meara said that he is working on a startup focused on Alzheimer’s, a disease that is personal to his family. His grandmother, who he was particularly close to, was diagnosed with the disease when he was growing up. “She suffered a lot from Alzheimer’s. It’s a tragic, terrible condition that you lose them so far before they actually go,” he said. “That was always something that left its mark on me.” He said that he had dabbled in starting an Alzheimer’s company before Ochre. Now, he says that investors have warmed up to the idea more. “In light of the recent approvals, [I’m] starting to see a little bit of hope for a company there. And those two approvals leave a lot of room to be desired for impactful new medicines,” he said. The FDA approved Eli Lilly’s Alzheimer’s treatment Kisunla earlier this year, and Biogen and Eisai’s Leqembi in 2023. O’Meara noted that he grew up in Athlone, Ireland — where Elan Corporation was founded. Elan was a major drug company that had tried and failed to develop an Alzheimer’s drug with Johnson & Johnson and Pfizer (via its acquisition of Wyeth). O’Meara said he’s just “beginning to piece together the puzzle” for this new startup.